abs332.txt	background		the	objective	of	this	study	was	to	demonstrate	the	feasibility	andefficacy	of	induction	chemotherapy		surgery		and	pathology-guided	adjuvanttherapy	to	treat	transorally	resectable	squamous	head	and	neck	cancer	methods		patients	had	squamous	head	and	neck	cancer	that	was	resectable	by	thetransoral	route	and	advanced-stage	disease	(american	joint	committee	on	cancerstage	iii-iv		t3-t4	tumors		and/or	positive	lymph	nodes)		they	received	treatmentwith	weekly	carboplatin	at	an	area	under	the	curve	of	2		plus	paclitaxel135	mg/m2			and	daily	lapatinib	1000mg	for	6	weeks	followed	by	surgicalresection		pathology	that	revealed	margins	<5	mm		extracapsular	extension		n2a	ofn2b	lymph	node	status		perineural	invasion		or	lymphovascular	space	invasionresulted	in	adjuvant	radiotherapy	concurrent	with	weekly	cisplatin		pathologywith	n2c/n3	lymph	node	status	or	positive	margins	resulted	in	radiation	withbolus	cisplatin		the	primary	endpoint	was	the	clinical	response	rate	to	inductionchemotherapy		and	a	key	secondary	endpoint	was	feasibility	results		toxicity	was	modest		and	37	of	40	patients	completed	study	procedures	asplanned		the	clinical	response	rate	was	93%		the	pathologic	complete	responserate	was	36%		and	the	clinical	response	did	not	predict	for	a	pathologic	completeresponse		no	patient	on	study	follow-up	has	recurred	or	died		twenty-nine	of	39patients	who	underwent	surgery	avoided	radiation		speech	and	swallowing	functionwere	well	preserved	conclusions		the	study	met	both	its	primary	efficacy	endpoint	and	the	secondaryfeasibility	endpoint		neoadjuvant		systemic	therapy	and	surgical	resectionfollowed	by	risk-adapted	adjuvant	therapy	resulted	in	high	response	rates	andexcellent	long-term	outcomes	and	should	be	further	studied		cancer2018	124	2986-92		Â©	2018	american	cancer	society	
